Rafarma Pharmaceuticals Stock Current Valuation
| RAFA Stock | USD 0.18 0.04 28.57% |
Valuation analysis of Rafarma Pharmaceuticals helps investors to measure Rafarma Pharmaceuticals' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Rafarma Pharmaceuticals' price fluctuation is out of control at this time. Calculation of the real value of Rafarma Pharmaceuticals is based on 3 months time horizon. Increasing Rafarma Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Rafarma Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Rafarma Pink Sheet. However, Rafarma Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.18 | Real 0.13 | Hype 0.18 | Naive 0.16 |
The real value of Rafarma Pink Sheet, also known as its intrinsic value, is the underlying worth of Rafarma Pharmaceuticals Company, which is reflected in its stock price. It is based on Rafarma Pharmaceuticals' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Rafarma Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Rafarma Pharmaceuticals helps investors to forecast how Rafarma pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Rafarma Pharmaceuticals more accurately as focusing exclusively on Rafarma Pharmaceuticals' fundamentals will not take into account other important factors: Rafarma Pharmaceuticals Company Current Valuation Analysis
Rafarma Pharmaceuticals' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Rafarma Pharmaceuticals Current Valuation | 7.89 M |
Most of Rafarma Pharmaceuticals' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Rafarma Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Rafarma Pharmaceuticals has a Current Valuation of 7.89 M. This is 99.95% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The current valuation for all United States stocks is 99.95% higher than that of the company.
Rafarma Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Rafarma Pharmaceuticals' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Rafarma Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Rafarma Pharmaceuticals by comparing valuation metrics of similar companies.Rafarma Pharmaceuticals is currently under evaluation in current valuation category among its peers.
Rafarma Fundamentals
| Return On Equity | -7.0E-4 | |||
| Return On Asset | -4.0E-4 | |||
| Profit Margin | (0.88) % | |||
| Operating Margin | (0.81) % | |||
| Current Valuation | 7.89 M | |||
| Price To Earning | (1.29) X | |||
| Price To Sales | 857.77 X | |||
| Net Income | (14.85 K) | |||
| Book Value Per Share | 40.49 X | |||
| Cash Flow From Operations | (1 K) | |||
| Earnings Per Share | (0.01) X | |||
| Beta | -0.39 | |||
| Market Capitalization | 110.29 M | |||
| Total Asset | 460.33 M | |||
| Retained Earnings | (2.38 M) | |||
| Current Liabilities | 292 K | |||
| Net Asset | 460.33 M |
About Rafarma Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Rafarma Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Rafarma Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Rafarma Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Rafarma Pink Sheet
Rafarma Pharmaceuticals financial ratios help investors to determine whether Rafarma Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Rafarma with respect to the benefits of owning Rafarma Pharmaceuticals security.